Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mylan NV Ord Shs (MYL)

Mylan NV Ord Shs (MYL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,641,365
  • Shares Outstanding, K 516,133
  • Annual Sales, $ 11,434 M
  • Annual Income, $ 352,500 K
  • 60-Month Beta 1.72
  • Price/Sales 0.85
  • Price/Cash Flow 2.25
  • Price/Book 0.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.29
  • Number of Estimates 7
  • High Estimate 1.32
  • Low Estimate 1.27
  • Prior Year 1.30
  • Growth Rate Est. (year over year) -0.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.57 +3.14%
on 02/28/20
23.11 -26.05%
on 02/06/20
-4.75 (-21.75%)
since 01/28/20
3-Month
16.57 +3.14%
on 02/28/20
23.11 -26.05%
on 02/06/20
-1.69 (-9.00%)
since 11/27/19
52-Week
16.57 +3.14%
on 02/28/20
29.30 -41.67%
on 03/21/19
-9.30 (-35.24%)
since 02/28/19

Most Recent Stories

More News
Mylan's (MYL) Q4 Earnings Beat, Revenues Miss Estimates

Mylan's (MYL) earnings beat estimates but sales miss the same in the fourth quarter of 2019.

PFE : 32.89 (-3.55%)
MYL : 17.07 (-8.62%)
GSK : 40.01 (-3.80%)
TBPH : 23.52 (-1.67%)
Mylan (MYL) Tops Q4 Earnings Estimates

Mylan (MYL) delivered earnings and revenue surprises of 8.53% and -0.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

MYL : 17.07 (-8.62%)
Mylan Reports Fourth Quarter and Full Year 2019 Results and Provides 2020 Guidance

Mylan N.V. (NASDAQ: MYL) today announced its financial results for the fourth quarter and the year ended December 31, 2019 and provided 2020 guidance.

MYL : 17.07 (-8.62%)
Momenta's (MNTA) Q4 Loss Wider than Expected, Sales Beat

Momenta (MNTA) reports mixed Q4 results, with a wider-than-expected loss and revenues beating the same.

TEVA : 11.64 (-4.67%)
REGN : 433.29 (+0.39%)
MYL : 17.07 (-8.62%)
MNTA : 27.31 (-3.77%)
Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer

Mylan N.V. (NASDAQ: MYL) and Pfizer (NYSE: PFE) today announced that Sanjeev Narula, current chief financial officer (CFO) of Upjohn, a division of Pfizer, has been named incoming CFO of Viatris, the new...

MYL : 17.07 (-8.62%)
PFE : 32.89 (-3.55%)
Mylan and Pfizer Finalize Appointments to Viatris Board of Directors

Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced the remaining appointees to the inaugural 13-member Board of Directors for Viatris, the new company that will result from the combination...

MYL : 17.07 (-8.62%)
PFE : 32.89 (-3.55%)
Shares of Mylan Nv Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (MYL , PFE , ZTS , BMY , PRGO )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

MYL : 17.07 (-8.62%)
PFE : 32.89 (-3.55%)
ZTS : 129.21 (-3.54%)
Is a Surprise Coming for Mylan (MYL) This Earnings Season?

Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

MYL : 17.07 (-8.62%)
Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates

Theravance (TBPH) reports earnings miss in the fourth quarter while sales beat estimates.

JNJ : 133.33 (-4.16%)
PFE : 32.89 (-3.55%)
MYL : 17.07 (-8.62%)
TBPH : 23.52 (-1.67%)
Air Transport (ATSG) to Report Q4 Earnings: What's in Store?

Low fuel costs are likely to have aided Air Transport Services' (ATSG) fourth-quarter earnings performance.

MYL : 17.07 (-8.62%)
ATSG : 16.98 (-3.03%)
LTM : 6.86 (-1.15%)
AZUL : 28.77 (-5.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade MYL with:

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Key Turning Points

2nd Resistance Point 19.99
1st Resistance Point 19.34
Last Price 17.07
1st Support Level 18.19
2nd Support Level 17.69

See More

52-Week High 29.30
Fibonacci 61.8% 24.44
Fibonacci 50% 22.93
Fibonacci 38.2% 21.43
Last Price 17.07
52-Week Low 16.57

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar